Hamadani, M. (2022) “Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?”, Haematologica. Pavia, Italy, 107(7), pp. 1500-1502. doi: 10.3324/haematol.2021.280284.